Holen Sie sich die Stockscreener-App
2.255
0.67%
0.015
Schlusskurs vom Vortag:
$2.24
Offen:
$2.25
24-Stunden-Volumen:
152.44K
Relative Volume:
0.35
Marktkapitalisierung:
$155.51M
Einnahmen:
$8.38M
Nettoeinkommen (Verlust:
$-27.19M
KGV:
-2.0688
EPS:
-1.09
Netto-Cashflow:
$-13.59M
1W Leistung:
+5.87%
1M Leistung:
+6.37%
6M Leistung:
+125.50%
1J Leistung:
+97.81%
1-Tages-Spanne:
$2.14
$2.28
1-Wochen-Bereich:
$1.965
$2.29
52-Wochen-Spanne:
$0.65
$2.37
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Vergleichen Sie IRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
2.255 | 153.79M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.68 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.69 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.86 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
899.98 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.78 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-29 | Eingeleitet | Wedbush | Outperform |
| 2025-10-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Is Opus Genetics Inc. stock positioned well for digital economy2025 Earnings Impact & Daily Market Momentum Tracking - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades after rate cutsMarket Risk Analysis & Smart Allocation Stock Reports - Newser
Why Opus Genetics Inc. (R3X1) stock gets analyst attentionOptions Play & High Accuracy Trade Signal Alerts - Newser
Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades under stagflationAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser
Why institutional investors increase stakes in Opus Genetics Inc. (R3X1) stockMarket Growth Summary & Verified Entry Point Signals - Newser
Will Opus Genetics Inc. (R3X1) stock outperform small cap peers2025 Market WrapUp & Growth Focused Stock Reports - Newser
Brokers Issue Forecasts for Opus Genetics FY2025 Earnings - Defense World
Opus Genetics (NASDAQ:IRD) Upgraded to "Strong-Buy" at Brookline Capital Management - MarketBeat
Why Opus Genetics Inc. stock remains on buy listsJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - Newser
Brookline Capital Management Upgrades Opus Genetics (NASDAQ:IRD) to Strong-Buy - Defense World
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Why Opus Genetics Inc. (R3X1) stock remains stable2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser
Will Opus Genetics Inc. (R3X1) stock test record highs in 2025Weekly Profit Summary & Long-Term Capital Growth Strategies - Newser
Brookline Capital Markets initiates Buy rating on Opus Genetics stock By Investing.com - Investing.com Canada
Opus Genetics, Inc.'s (NASDAQ:IRD) large institutional owners must be happy as stock continues to impress, up 12% over the past week - simplywall.st
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT - Insider Monkey
Opus Genetics (NASDAQ:IRD) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
Opus Genetics (NASDAQ:IRD) Coverage Initiated at Piper Sandler - MarketBeat
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Piper Sandler Initiates Coverage on IRD with Overweight Rating a - GuruFocus
Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage - TradingView
Piper Sandler initiates coverage on Opus Genetics stock with Overweight rating - Investing.com Canada
Opus Genetics, Inc. $IRD is BIOS Capital Management LP’s 2nd Largest Position - Defense World
Opus Genetics Inc R3X1 Stock Analysis and ForecastCurrency Fluctuation Impact & Consistent High Yield Stocks - earlytimes.in
Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know - MSN
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Bristol-Myers Squibb (BMY) and PACS Group Inc (PACS) - The Globe and Mail
How Opus Genetics Inc. (R3X1) stock reacts to fiscal policies2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
Is Opus Genetics Inc. (R3X1) stock a safe buy pre earningsJuly 2025 Patterns & Verified Technical Signals - newser.com
What is the fair value estimate for Opus Genetics Inc. (R3X1) stock in 2025Take Profit & Risk Controlled Daily Trade Plans - newser.com
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
Opus Genetics to Participate in Upcoming Investment Conferences - The Manila Times
Will Opus Genetics Inc. (R3X1) stock rise with strong economy2025 Price Momentum & Fast Gain Stock Trading Tips - newser.com
Is Opus Genetics Inc. stock positioned for digital transformationJuly 2025 Volume & Daily Entry Point Alerts - newser.com
Can Opus Genetics Inc. stock attract ESG capital inflows2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
Opus Genetics, Inc.Common Stock (NQ: IRD - Markets Financial Content
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):